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Abstract
Objective To evaluate whether the prevalence of HIV-1 transmitted drug
resistance has continued to decline in infections probably acquired within
the United Kingdom.
Design Multicentre observational study.
Setting All UK public laboratories conducting tests for genotypic HIV
resistance as a part of routine care.
Participants 14 584 patients infected with HIV-1 subtype B virus, who
were first tested for resistance before receiving antiretroviral therapy
between January 2002 and December 2009.
Main outcome measure Prevalence of transmitted drug resistance,
defined as one or more resistance mutations from the surveillance list
recommended by the World Health Organization.
Results 1654 (11.3%, 95% confidence interval 10.8% to 11.9%) patients
had one or more mutations associated with transmitted HIV-1 drug
resistance; prevalence was found to decline from 15.5% in 2002 to 9.6%
in 2007, followed by a slight increase to 10.9% in 2009 (P=0.21). This
later rise was mainly a result of increases in resistance to nucleos(t)ide
reverse transcriptase inhibitors (from 5.4% in 2007 to 6.6% in 2009,
P=0.24) and protease inhibitors (1.5% to 2.1%, P=0.12). Thymidine
analogue mutations, including T215 revertants, remained the most
frequent mutations associated with nucleos(t)ide reverse transcriptase
inhibitors, despite a considerable fall in stavudine and zidovudine use
between 2002 and 2009 (from 29.4% of drug regimens in 2002 to 0.8%
in 2009, from 47.9% to 8.8%, respectively).
Conclusions The previously observed decline in the prevalence of
transmitted drug resistance in HIV-1 infections probably acquired in the
UK seems to have stabilised. The continued high prevalence of thymidine
analogue mutations suggests that the source of this resistance may be
increasingly from patients who have not undergone antiretroviral therapy
and who harbour resistant viruses. Testing of all newly diagnosed HIV-1
positive people should be continued.
Introduction
Combination antiretroviral therapy continues to be highly
effective in treating HIV-1, and the introduction of new drugs
and antiretroviral drug classes has notably improved patient
prognosis. Nevertheless, resistance to antiretroviral drugs can
develop in people on therapy and is associated with treatment
failure.1Against this backdrop, the rate of newHIV-1 infections
within the United Kingdom continues to rise.2 In such new
infections, transmitted drug resistance is sometimes assumed
to reflect only direct infection from patients already receiving
antiretroviral therapy. Concerns about an adverse effect of
transmitted HIV-1 drug resistance on the success of antiretroviral
therapy have led to national and international guidelines
recommending that all newly diagnosed patients have resistance
tests conducted to aid selection of first line regimens.3 4
A previous study showed a sharp decline in the prevalence of
transmitted HIV-1 drug resistance in the UK between 2002 and
2005,5 which was mainly attributed to changes in testing
guidelines and the wider use of regimens that suppress viral
concentrations to below infectious levels. Since then, more
potent and better tolerated antiretroviral drugs have been
introduced, and the proportion of patients achieving viral
suppression has continued to increase.6 This suggests that
transmitted HIV-1 drug resistance may have declined even
further and could eventually fall below levels in which universal
testing before antiretroviral therapy is cost effective,7 an
important issue at a time when the cost of HIV-1 management
is being scrutinised.8 This paper examines recent time trends in
transmitted drug resistance in HIV-1 infections probably
acquired in the UK.
Methods
Resistance data
The UK HIV Drug Resistance Database, described in detail
elsewhere,9 was established in 2001 and collects the majority
of genotypic resistance tests done within the UK as part of
routine clinical care. The resistance tests analysed in this study
used bulk sequencing of the pol gene, encoding at least codons
4-99 of the protease gene and 34-234 of the reverse transcriptase
gene, using a variety of inhouse and commercial testing systems.
Subtype was assigned centrally using the Rega algorithm.10
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Clinical data
We acquired demographic and clinical information by linkage
(using pseudonymised identifiers) to the UKCollaborative HIV
Cohort Study (UK CHIC),9 which includes patients from 13 of
the largest clinics within the UK, and to the HIV and AIDS
Patient and the Survey of Prevalent HIV Infections Diagnosed
databases, which are coordinated by the Health Protection
Agency. When possible, we linked resistance tests done after
2007 to samples on which a recent infection testing algorithm
had been conducted as part of a national health surveillance
programme11; these tests use antibody avidity assays to classify
infections as either recent (probably occurring in the previous
five months) or non-recent;12 and clinical, laboratory, or
historical information to reduce the false recent rate.
Tests included in analysis and definition of
drug resistance
The UK has several parallel and largely non-overlapping HIV-1
epidemics with different levels and patterns of resistance to
antiretroviral therapy.13 14 To simplify the understanding of
temporal trends, we limited this analysis to subtype B viral
infections, so it is not intended to generate nationally
representative results. This epidemic was seeded by around six
introductions to the UK in the early to mid-1980s15 and is largely
confined to men infected through homosexual exposure, of
whom 83% are estimated to have acquired infection within the
UK.16
We identified the first resistance test for all patients older than
16 years who had not yet received antiretroviral therapy at the
time of sampling, up to the end of 2009. Patients with an
undetectable viral load (<50 copies/mL) were excluded; such
levels may indicate unrecorded treatment use. Since guidelines
in 2001 first recommended that resistance tests be performed
for all patients who had not received antiretroviral therapy,3 we
excluded tests conducted before 2002.
Transmitted HIV-1 drug resistance was defined as one or more
mutations from the surveillance list recommended by theWorld
Health Organization.17 We used the Stanford HIVdb algorithm
6.0.11 (29Mar 2011) to examine susceptibility to antiretroviral
drugs, and reported low level resistance or greater. Intermediate
or high level resistance was considered to reflect a substantial
loss in susceptibility. We assessed temporal trends in terms of
the date of the resistance test sample rather than the date of the
patient’s infection, which is generally not known.
Statistical methods
Confidence intervals for proportions were calculated using a
95%Wilson confidence interval for binomially distributed data.
We analysed the patterns of trends over continuous time using
both linear and piecewise linear logistic regression with a
flexible choice of a single inflexion point calculated using least
squares optimisation; we selected the model with the best fit
according to Akaike’s information criterion. The trends for
codons were reported if a mutation had an overall prevalence
of more than 0.3% as well as other mutations for nucleos(t)ide
reverse transcriptase with a strong effect on phenotype (K65R,
K70E, L74I/V, Y115F). We examined differences between the
prevalence of resistance in recent and non-recent infections tests
using the χ2 test. All statistical analyses were conducted in
Stata/IC 11.2 software.
Results
Population characteristics
We analysed 14 583 patients who were antiretroviral therapy
naive, infected with a subtype B virus, and whose first drug
resistance test was conducted between January 2002 and
December 2009. Of these patients, 10 173 (70%) were white,
995 (7%) were black, 711 (5%) had a known other ethnicity,
and 2704 (19%) had an unknown ethnicity. The median age at
diagnosis was 36 years (interquartile range 30 to 42). Of the
patients analysed, 10 288 (71%) were men who had sex with
men, 1275 (9%) had a heterosexual exposure source, 313 (2%)
had a known other exposure source, and 2707 (19%) had an
unknown exposure source. Themedian number of days between
HIV-1 diagnosis and resistance sample was 22 (interquartile
range five to 358). Themedian CD4 count at the time of testing,
available from 11 219 (76.9%) patients, was 408×106 cells/L
(interquartile range 271×106 to 560×106).
The number of resistance tests conducted per year increased
over time, reflecting a rise in the number of new diagnoses
among men who have sex with men (fig 1⇓). The decline
between 2008 and 2009 is mainly due to an increase in the
proportion of tests where the patient’s status regarding
antiretroviral therapy exposure was uncertain (15.6% in 2008
to 32.0% in 2009), probably as a result of a reporting lag with
demographic and clinical datasets.
Trends in transmitted drug resistance
Samples from 1654 (11.3%, 95% confidence interval 10.8% to
11.9%) patients had one or more mutations associated with
transmitted HIV-1 drug resistance. Of these samples, 1009
(6.9%, 6.5% to 7.3%), 604 (4.1%, 3.8% to 4.5%), and 319
(2.2%, 2.0% to 2.4%) had one or more mutations associated
with nucleos(t)ide reverse transcriptase inhibitors,
non-nucleoside reverse transcriptase inhibitors, and protease
inhibitors, respectively. Of these samples, 1426 (9.8%, 9.3% to
10.3%) had single class resistance, 175 (1.2%, 1.0% to 1.4%)
had dual class resistance, and 52 (0.4%, 0.3% to 0.5%) had triple
class resistance; dual and triple class resistance have remained
at a similar prevalence since 2005.
The previously reported5 decline in the prevalence of transmitted
HIV-1 drug resistance for any class of antiretroviral drug was
observed to continue from 15.5% in 2002 until around January
2007 (95% confidence interval January 2006 to February 2008;
odds ratio 0.88 per year (95% confidence interval 0.84 to 0.92);
fig 1). However, between 2007 and 2009, we saw a
non-significant increase from 9.6% to 10.9% (odds ratio 1.06,
0.97 to 1.17; P=0.21). We saw non-significant increases in
resistance to nucleos(t)ide reverse transcriptase inhibitors (from
5.4% in 2007 to 6.6% in 2009; P=0.24) and protease inhibitors
(1.5% to 2.1%; P=0.12). Inflection points were also identified,
which gave a significantly better fit for mutations associated
with nucleos(t)ide reverse transcriptase inhibitors (February
2007 (January 2006 to March 2008); second piece odds ratio
1.08 (0.95 to 1.22)) and protease inhibitors (June 2008 (August
2007 to June 2009); 1.69 (0.86 to 3.31)). The prevalence of
mutations associated with non-nucleoside reverse transcriptase
inhibitors remained stable at around 3.6% with no evidence of
non-linearity (odds ratio 0.96 (0.92 to 1.00)).
The table⇓ displays the resistance trends over time for key
individual codons with prevalence greater than 0.3%. The trends
in HIV-1 drug resistance associated with nucleos(t)ide reverse
transcriptase inhibitors largely reflect the most common
mutations within this drug class, namely, the T215 revertant18
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mutations (I/S/C/D/V/E), K219Q/E/N/R, and M41L. These
mutations are either reversions or a subset of the thymidine
analogue mutations that develop under regimens containing
either stavudine or zidovudine. The finding of a levelling off in
the prevalence of thymidine analogue mutations is paradoxical,
in the light of the dramatic fall in the use of stavudine and
zidovudine. For example, in the UKCHIC study, the proportion
of treatment regimens that included stavudine dropped from
29.4% to 0.8% between 2002 and 2009, while the proportion
that included zidovudine dropped from 47.9% to 8.8% over the
same period. Stavudine and zidovudine have largely been
replaced by tenofovir and abacavir,3 but signature mutations for
these drugs (such as K65R) are still rare in patients with HIV-1.
L90M mutations have increased in prevalence since 2007,
despite the near cessation in the use of saquinavir, nelfinavir,
and indinavir, which are first generation protease inhibitors that
select for this mutation (their use in the UK as part of a drug
regimen fell from 20.6% in 2002 to 4.6% in 2009), although
L90M has broad cross resistance effects to the protease inhibitor
class.19
Drug susceptibility
Figure 2⇓ shows the predicted susceptibility of HIV-1 from
samples collected in 2009 to currently recommended first line
antiretroviral drugs3 and second generation antiretroviral drugs
darunavir and etravirine. The association between genotypic
mutations and the phenotypic susceptibility to antiretroviral
drugs is complex, so although T215 revertants are considered
by the Stanford HIVdb algorithm to result in only low level
resistance to nucleos(t)ide reverse transcriptase inhibitors, they
do confer a low genetic barrier to the development of high level
resistance to this drug class.
The prevalence of intermediate or high level resistance to
nucleos(t)ide reverse transcriptase inhibitors other than
zidovudine was less than 0.9%, reflecting the low frequency of
multiple mutations in thymidine analogues. There was a
comparatively high level of reduced susceptibility to
recommended first line regimens of the non-nucleoside reverse
transcriptase inhibitors efavirenz and nevirapine (3.7%).
However, etravirine, a non-nucleoside reverse transcriptase
inhibitor, displayed very low levels of resistance (0.4%),
reflecting the lack of predicted effect of K103N. The potency
of modern drugs from the protease inhibitor class was high (only
25 (1.1%) patients had substantially reduced susceptibility to
any protease inhibitor), owing to the rarity of multiple protease
mutations. These findings indicate that potent first line regimens
can still be constructed from the original three drug classes for
almost all patients.
Prevalence of resistance in recently infected
patients
Between 2007 and 2009, 742 samples were linked to a recent
infection test result, of which 171 (23.0%) were classified as
recent. The overall prevalence of resistance did not differ
significantly (P=0.66) between recent samples (20, 11.7%) or
non-recent samples (60/571, 10.5%). Furthermore, we detected
no significant differences in the prevalence of resistance by
individual drug class (results not shown).
Discussion
Interpretation
The previously observed decline in the prevalence of transmitted
drug resistance in subtype B viruses seems to have been reversed
for mutations associated with nucleos(t)ide reverse transcriptase
inhibitors and protease inhibitors, despite an increase in the
proportion of patients on antiretroviral therapy who are
virologically suppressed (from 62% in 2000 to 84% in 20076).
The most frequent mutations were T215 revertants, which may
be transmitted as such or evolve from a virus harbouring a
T215F or T215Y mutation.19 These and other mutations are
associated with a significantly higher risk of virological failure
than wild type genotypes.1 17 The prevalence of transmitted
thymidine analogue mutations remained moderately high,
despite a marked shift away from the prescribing in the UK of
drugs that select for these mutations.
One plausible explanation for this paradox is the onward
transmission of resistant viruses from people who have not
received antiretroviral therapy before and who were themselves
infected with a resistant virus. This hypothesis is supported by
a previous phylogenetic analysis of UK subtype B sequences,
which described five transmission clusters comprised exclusively
of patients with resistance mutations who are antiretroviral
therapy naive.20 It was postulated that an increasingly greater
proportion of transmitted HIV-1 drug resistance could originate
from antiretroviral therapy naive lineages, and that there could
ultimately be a limit in the decline of transmitted HIV-1 drug
resistance.
The first factor contributing to this possible limit is that people
with undiagnosed HIV could disproportionally21 spread the
epidemic, since they are more infectious in the period
immediately after infection.22 Some studies23 24 (but not all25)
have also shown that undiagnosed patients with HIV havemore
sexual partners than diagnosed patients. Furthermore, evidence
is emerging that transmitted resistant viruses are more persistent
than originally thought. The fitness cost (relative to wild type
virus) of certain mutations, such as the T215 revertants and
K103N, has been shown to be marginal in laboratory studies.26 27
Jain and colleagues provided clinical confirmation of this finding
in a series of patients infected with resistant virus and who had
two or more resistance tests before they started antiretroviral
therapy.28 With the exception of the M184V mutation, which is
highly replicatively deficient, all groups of transmittedmutations
persisted beyond at least three years in the majority of patients.
A second possible explanation for the continued prevalence of
thymidine analogue mutations is that the use of tenofovir and
abacavir are maintaining the prevalence of such mutations in
patients who have received antiretroviral therapy despite the
decline in the use of zidovudine and stavudine. Further
phylogenetic research could shed light on the transmission
dynamics of these mutations.
Comparison with other studies
Two recent studies have reported on time trends in transmitted
HIV drug resistance. In a study conducted in 20 European
countries between 2002 and 2006,29Vercauteren and colleagues
found a small, linear decline in levels of nucleos(t)ide reverse
transcriptase inhibitor and protease inhibitor resistance;
non-nucleoside reverse transcriptase inhibitor resistance was
observed to increase followed by a decrease between 2004 and
2006. Bartmeyer and colleagues30 performed a similar analysis
of a German seroconverter cohort between 1996 and 2007. In
more recent years, resistance to nucleos(t)ide reverse
transcriptase inhibitors seemed to be stable and resistance to
non-nucleoside reverse transcriptase inhibitors seemed to
increase, although clear patterns are difficult to discern due to
the relatively small sample size.
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Study limitations
Our study has several limitations. Firstly, the analysis is based
on resistance found at date of sample rather than date of
infection. Since viral quasi-species harbouring resistance
mutations may revert to, or be overgrown by, virus without the
mutations,19 29 the true level of transmitted HIV drug resistance
may have been under-estimated in this analysis. Also, the degree
of this bias will be affected by the average time between HIV-1
infection and diagnosis, which may have changed over time.
Furthermore, the diagnosis delay could mask the underlying
trend in the prevalence of transmitted resistance by date of
infection. However, we found no difference in the prevalence
of resistance between recent and non-recent infections, in the
subset of patients in which this analysis was possible.
Secondly, the genotypic data analysed were generated by
population sequencing with a limit of sensitivity of
approximately 15 to 25%.31 32 Our estimates of the prevalence
of transmitted HIV drug resistance may therefore be biased
downwards. This will have also biased the type of mutations
observed, with persistent mutations appearing to be more
prevalent than those which rapidly become undetectable such
as K65R or M184V. We do not consider this limitation to be a
major concern, because the main objective of our study was to
examine changes in the prevalence of transmitted HIV drug
resistance over time.
Another limitation was that our method of classifying treatment
status could have resulted in misclassification bias if some
patients who had received antiretroviral therapy were included
in the analysis. Previous research by the UK HIV Drug
Resistance Database has suggested that this effect could distort
trends if there is misclassification in 4% or more of the samples
analysed.33 Finally, as the prevalence of transmitted HIV drug
resistance in subtype B viruses, the focus of this analysis, is
known to be higher than that observed in other subtypes,34 our
findings are not generalisable to the UK epidemic as a whole,
although coverage of patients infected with subtype B virus is
high.
Conclusions and policy implications
Finally, we consider the clinical implications of our main
conclusion that resistant lineages may have become fixed in the
circulating viral pool. This concept, if confirmed to be correct,
will apply universally, particularly in countries where first
generation nucleos(t)ide reverse transcriptase inhibitors continue
to be used, and underscores the importance of sentinel
surveillance. In terms of the UK (and probably other well
resourced countries), the detectable mutations that tend to be
transmitted should have little effect on nucleos(t)ide reverse
transcriptase inhibitors currently used in first line regimens, that
is, abacavir, tenofovir, lamivudine, and emtricitabine.
Non-nucleoside reverse transcriptase inhibitors used in first line
regimens are of greater concern, with approximately 4% of
patients being infected with viruses with reduced susceptibility
to efavirenz and nevirapine. Previous models7 have suggested
that baseline resistance testing remains cost effective at the
levels observed in this study. Therefore, our findings argue that
testing at HIV diagnosis and continued monitoring should
remain the standard of care.
The UK Collaborative Group on HIV Drug Resistance is a collaboration
between the UK HIV Drug Resistance Database; UK CHIC; Health
Protection Agency HARS; and participating academic centres, clinics,
and laboratories.
Analysis/writing group: David Dolling, Caroline Sabin, Valerie Delpech,
Erasmus Smit, Anton Pozniak, David Asboe, Andrew Leigh Brown,
Duncan Churchill, Ian Williams, Anna Maria Geretti, Andrew Phillips,
Nicola Mackie, Gary Murphy, Hannah Castro, Deenan Pillay, Patricia
Cane, David Dunn. David Dolling is the guarantor.
Steering Committee: Celia Aitken, Gartnavel General Hospital, Glasgow;
David Asboe, Anton Pozniak, Chelsea and Westminster Hospital,
London; Clare Booth, Royal Free NHS Trust, London; Patricia Cane,
Health Protection Agency, Porton Down; Hannah Castro, Jonathan
Crofts, David Dunn (co-chair), David Dolling, Esther Fearnhill, Kholoud
Porter, MRC Clinical Trials Unit, London; David Chadwick, South Tees
Hospitals NHS Trust, Middlesbrough; Duncan Churchill, Brighton and
Sussex University Hospitals NHS Trust; Duncan Clark, St Bartholomew’s
and The London NHS Trust; Simon Collins, HIV i-Base, London; Valerie
Delpech, Health Protection Agency, Centre for Infections, London; Anna
Maria Geretti, University of Liverpool; David Goldberg, Health Protection
Scotland, Glasgow; Antony Hale, Leeds Teaching Hospitals NHS Trust;
Stéphane Hué, University College London; Steve Kaye, Imperial College
London; Paul Kellam,Wellcome Trust Sanger Institute and UCLMedical
School; Linda Lazarus, Expert Advisory Group on AIDS Secretariat,
Health Protection Agency, London; Andrew Leigh-Brown, University of
Edinburgh; Nicola Mackie, Imperial NHS Trust; Chloe Orkin, St.
Bartholomew’s Hospital, London; Philip Rice, St George’s Healthcare
Trust, London; Deenan Pillay (co-chair), Andrew Phillips, Caroline Sabin,
University College London Medical School; Erasmus Smit, Health
Protection Agency, Birmingham Heartlands Hospital; Kate Templeton,
Royal Infirmary of Edinburgh; Peter Tilston, Manchester Royal Infirmary;
William Tong, Guy’s and St. Thomas’ NHS Foundation Trust, London;
Ian Williams, Mortimer Market Centre, London; Hongyi Zhang,
Addenbrooke’s Hospital, Cambridge; Mark Zuckerman, King’s College
Hospital, London.
Centres contributing data: Clinical Microbiology and Public Health
Laboratory, Addenbrooke’s Hospital, Cambridge (Jane Greatorex);
HIV/GUM Research Laboratory, Chelsea and Westminster Hospital,
London (AdrianWildfire); Guy’s and St. Thomas’ NHS Foundation Trust,
London (SiobhanO’Shea, JaneMullen); HPA – Public Health Laboratory,
Birmingham Heartlands Hospital, Birmingham (Erasmus Smit); HPA
London (Tamyo Mbisa); Imperial College Health NHS Trust, London
(Alison Cox); King’s College Hospital, London (Richard Tandy); Medical
Microbiology Laboratory, Leeds Teaching Hospitals NHS Trust (Tony
Hale, Tracy Fawcett); Specialist Virology Centre, Liverpool (Mark
Hopkins, Lynn Ashton); Department of Clinical Virology, Manchester
Royal Infirmary, Manchester (Peter Tilston); Department of
Virology, Royal Free Hospital, London (Clare Booth, Ana Garcia-Diaz);
Edinburgh Specialist Virology Centre, Royal Infirmary of Edinburgh (Jill
Shepherd); Department of Infection and Tropical Medicine, Royal Victoria
Infirmary, Newcastle (Matthias L Schmid, Brendan Payne); South Tees
Hospitals NHS Trust, Middlesbrough (David Chadwick); St George’s
Hospital, London (Phillip Hay, Phillip Rice, Mary Paynter); Department
of Virology, St Bartholomew’s and The London NHS Trust (Duncan
Clark, David Bibby); Molecular Diagnostic Unit, Imperial College, London
(Steve Kaye); University College London Hospitals (Stuart Kirk); West
of Scotland Specialist Virology Lab Gartnavel, Glasgow (Alasdair
MacLean, Celia Aitken, Rory Gunson).
Coordinating centre: Medical Research Council Clinical Trials Unit,
London (Kate Coughlin, Jonathan Crofts, David Dolling, David Dunn,
Esther Fearnhill, Kholoud Porter).
Funding: This work was supported by the UKMedical Research Council
(grant G0900274) and the European Community’s 7th framework
programme (FP7/2007-2013) under the Collaborative HIV and Anti-HIV
Drug Resistance Network (CHAIN; project 223131).
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: support from the UKMedical
Research Council and the European Community’s 7th framework
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e5253 doi: 10.1136/bmj.e5253 (Published 21 August 2012) Page 4 of 7
RESEARCH
What is already known on this topic
Transmitted HIV drug resistance can affect therapy success
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A 2007 paper has shown a reduction in transmitted drug resistance in the UK since 2005
What this study adds
Transmitted drug resistance is no longer declining in UK, and evidence suggests a sustained epidemic that is resistant to nucleos(t)ide
reverse transcriptase inhibitors, irrespective of previous antiretroviral therapy use
Susceptibility to antiretroviral therapy remains relatively high, and potent first line regimens can still be constructed from the original
three drug classes for almost all patients
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Table
Table 1| Time trends of selected mutations with prevalence greater than 0.3%. Data are no (%) of samples with mutation unless stated
otherwise
Year (no of samples)
Mutation 2009 (n=2221)2008 (n=2651)2007 (n=2525)2006 (n=2455)2005 (n=2054)2004 (n=1364)2003 (n=766)2002 (n=547)
Protease inhibitors
13 (0.59)15 (0.57)14 (0.55)14 (0.57)17 (0.83)13 (0.95)9 (1.17)12 (2.19)M46I/L
7 (0.32)3 (0.11)8 (0.32)7 (0.29)12 (0.58)19 (1.39)10 (1.31)9 (1.65)V82A/T/F/S/C/M
21 (0.95)16 (0.60)12 (0.48)18 (0.73)24 (1.17)20 (1.47)9 (1.17)8 (1.46)L90M
Non-nucleoside reverse transcriptase inhibitors
62 (2.79)89 (3.36)76 (3.01)67 (2.73)57 (2.78)40 (2.93)28 (3.66)21 (3.84)K103N/S
9 (0.41)12 (0.45)13 (0.51)11 (0.45)17 (0.83)10 (0.73)9 (1.17)5 (0.91)Y181C/I/V
3 (0.14)8 (0.3)8 (0.32)9 (0.37)14 (0.68)10 (0.73)7 (0.91)7 (1.28)G190A/S/E
Nucleos(t)ide reverse transcriptase inhibitors
33 (1.49)51 (1.92)41 (1.62)49 (2.00)49 (2.39)46 (3.37)17 (2.22)27 (4.94)M41L
03 (0.11)3 (0.12)1 (0.04)1 (0.05)3 (0.22)3 (0.39)1 (0.18)K65R
9 (0.41)13 (0.49)13 (0.51)21 (0.86)21 (1.02)20 (1.47)9 (1.17)12 (2.19)D67N/G/E
3 (0.14)4 (0.15)2 (0.08)6 (0.24)5 (0.24)4 (0.29)9 (1.17)6 (1.10)K70E*
1 (0.05)2 (0.08)3 (0.12)4 (0.16)5 (0.24)3 (0.22)3 (0.39)5 (0.91)L74I/V*
2 (0.09)1 (0.04)01 (0.04)1 (0.05)1 (0.07)2 (0.26)0Y115F*
7 (0.32)9 (0.34)14 (0.55)13 (0.53)15 (0.73)15 (1.1)13 (1.70)11 (2.01)M184I/V
8 (0.36)12 (0.45)9 (0.36)12 (0.49)13 (0.63)15 (1.1)7 (0.91)12 (2.19)L210W
2 (0.09)2 (0.08)3 (0.12)7 (0.29)17 (0.83)9 (0.66)9 (1.17)12 (2.19)T215Y/F
87 (3.92)102 (3.85)82 (3.25)86 (3.50)82 (3.99)59 (4.33)35 (4.57)35 (6.40)T215I/S/C/D/V/E
39 (1.76)41 (1.55)33 (1.31)34 (1.38)34 (1.66)31 (2.27)19 (2.48)10 (1.83)K219Q/E/N/R
*Included because these are major mutations to recommended first line antiretroviral drugs.
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Figures
Fig 1 Prevalence of transmitted drug resistance over time, by antiretroviral drug class. Bar=95% confidence interval
Fig 2 Predicted susceptibility to antiretroviral drugs
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